Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Pain
- Drugs
- Pharmaceuticals
- Disease
- Medical
- Delivery
- Device
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 32573
License Grant
The Licensor grants the Licensee an exclusive license under the Licensed Patents and Know-How to develop and to make, have made, use, sell, have sold and otherwise dispose of the Licensed Product, a pharmaceutical used for pain.
License Property
The Licensor owns or controls the rights to a proprietary drug product – the combination of celecoxib and dextromethorphan or any combination that includes celecoxib or dextromethorphan to treat neurological disorders and pain.
Field of Use
The Licensee is a biopharmaceutical research and development company. The Licensee shall be entitled to certain rights to develop and commercialize the Licensed Product.
The Field is limited to, veterinary and human therapeutic and diagnostic products and the manufacture, use and sale thereof.
IPSCIO Record ID: 280835
License Grant
Licensor grants Licensee an exclusive, sublicense under the Patents and license under the Know-How and Licensor Improvements to offer, make, have made, use, lease, export, import, sell and resell Products, use the Process or both in the Territory.
License Property
Licensor has developed certain additional technology and know-how related to the patents, patent applications and the medical use of dextromethorphan or a combination of dextromethorphan with quinidine or other enzyme inhibitors.
United States Patent Number 5,166,207, 'Method for Enhancing the Systemic Delivery of Dextromethorphan for the Treatment of Neurological Disorders'
United States Patent Number 5,166,207, 'Method for Enhancing the Systemic Delivery of Dextromethorphan for the Treatment of Neurological Disorders'
United States Patent Number 5,350,756, 'Use of a Cytochrome Oxidase Inhibitor to Increase the Cough-Suppressing Activity of Dextromethorphan'
United States Patent Number 5,366,980, 'Use of extromethorphan and an Oxidase Inhibitor to Treat Dermatitis'
United States Patent Number 5,863,927, 'Dextromethorphan and an Oxidase Inhibitor for Treating Intractable Conditions'
PCT Application PCT/US94/10771, 'Compositions Useful for the
Preparation of Medicines for Treating a Variety of Intractable Disorders'
United States Patent Application Number 09/471,060, filed December 22, 1999, entitled 'Dextromethorphan and Oxidase Inhibitor for Weaning Patients from Narcotics and Anti-Depressants'
Field of Use
Dextromethorphan or DM, is a well-known NMDA receptor antagonist. It has been reported in medical literature that DM is effective in reducing pain associated with diabetic neuropathy.
(i) EMOTIONAL LABILITY INDICATION.
(ii) CHRONIC PAIN INDICATION.
(iii) CHRONIC COUGH INDICATION.
(iv) DERMATITIS INDICATION.
(v) PRODUCTS FOR WEANING PATIENTS FROM NARCOTICS AND ANTI-DEPRESSANTS.
Emotional lability refers to rapid, often exaggerated changes in mood, where strong emotions or feelings (uncontrollable laughing or crying, or heightened irritability or temper) occur.
Dermatitis, also known as eczema, is a group of diseases that result in inflammation of the skin.
IPSCIO Record ID: 32572
License Grant
The Licensor grants to the Licensee in the Field and Territory, an exclusive license under the Licensed Patents and Know-How to develop and to make, have made, use, sell, have sold and otherwise dispose of the Licensed Product.
License Property
The Licensor owns or controls the rights to a proprietary drug product – any implantable polymeric device for sustained release of sufentanil or any combination that includes an implantable polymeric device for sustained release of sufentanil.
Used for epidural anesthesia, Sufentanil is a synthetic opioid.
Field of Use
“Field†means, and is limited to, veterinary and human therapeutic and diagnostic products and the manufacture, use and sale thereof.
The Licensee is a biopharmaceutical research and development company and shall be entitled to certain rights to develop and commercialize the Licensed Product.
IPSCIO Record ID: 282791
License Grant
The original agreement for commercialization of ConsensiTM in the U.S has been amended to include creating a near-term revenue streams to support further development of our oncology pipeline, engage a distribution partner with an established sales network and access to thousands of pharmacies to drive the launch of the drug. In addition, a marketing plan and pricing strategy have been finalized.
License Property
Licensor is a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance.
ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.
ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.
Field of Use
The Indications and Usage for Consensiâ„¢ is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
